Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis
暂无分享,去创建一个
S. Yusuf | M. Ezekowitz | S. Connolly | S. Hohnloser | J. Eikelboom | A. Siegbahn | Z. Hijazi | J. Oldgren | L. Wallentin | P. Reilly | U. Andersson
[1] M. Keltai,et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. , 2012, European heart journal.
[2] T. Lehr,et al. Dabigatran Etexilate in Atrial Fibrillation Patients With Severe Renal Impairment: Dose Identification Using Pharmacokinetic Modeling and Simulation , 2012, Journal of clinical pharmacology.
[3] Robby Nieuwlaat,et al. Revised A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey , 2012 .
[4] D. Singer,et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. , 2011, European heart journal.
[5] D. Atar,et al. Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[6] S. Yusuf,et al. Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial , 2011, Circulation.
[7] G. Lip,et al. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. , 2011, Journal of the American College of Cardiology.
[8] Elsayed Z Soliman,et al. Association of Chronic Kidney Disease With Atrial Fibrillation Among Adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study , 2011, Circulation. Arrhythmia and electrophysiology.
[9] R. Troughton,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[10] Gregory Y H Lip,et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.
[11] Jeroen J. Bax,et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[12] E. Lerma,et al. Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease. , 2010, American Society of Nephrology. Clinical Journal.
[13] B. Kestenbaum,et al. Impaired kidney function and atrial fibrillation in elderly subjects. , 2010, Journal of cardiac failure.
[14] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[15] G. Fonarow,et al. Quality of care for atrial fibrillation among patients hospitalized for heart failure. , 2009, Journal of the American College of Cardiology.
[16] Salim Yusuf,et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[17] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.
[18] S. Yusuf,et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. , 2009, American heart journal.
[19] G. Breithardt,et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. , 2009, Journal of the American Society of Nephrology : JASN.
[20] D. Singer,et al. Impact of Proteinuria and Glomerular Filtration Rate on Risk of Thromboembolism in Atrial Fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study , 2009, Circulation.
[21] Tom Greene,et al. Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate (Annals of Internal Medicine (2006) 145, (247-254)) , 2008 .
[22] Tom Greene,et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. , 2007, Clinical chemistry.
[23] L. Hansson,et al. Evaluation of Gentian cystatin C reagent on Abbott Ci8200 and calculation of glomerular filtration rate expressed in mL/min/1.73 m2 from the cystatin C values in mg/L , 2007, Scandinavian journal of clinical and laboratory investigation.
[24] R. Abbate,et al. Risk of bleeding in very old atrial fibrillation patients on warfarin: relationship with ageing and CHADS2 score. , 2007, Thrombosis research.
[25] Tom Greene,et al. Assessing kidney function--measured and estimated glomerular filtration rate. , 2006, The New England journal of medicine.
[26] Bruce M Psaty,et al. The presence of frailty in elderly persons with chronic renal insufficiency. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.